Showing 2841 results for "amyotrophic lateral sclerosis (ALS)"

Filter By

It's easy to feel isolated when dealing with a chronic disease like ALS, but help and support is available. For those who may need a little extra guidance or reassurance, we’ve compiled a variety of tips and advice from our ALS community that you may find useful.

Masitinib as an oral add-on therapy to Rilutek (riluzole) showed the greatest benefits in amyotrophic lateral sclerosis (ALS) patients with mild or moderate disease severity, an analysis of trial data showed. The findings come from the now-complete AB10015 Phase 2/3 clinical trial (NCT02588677) that excluded people…

Neuvivo’s NP001 (sodium chlorite) may help slow the progression of amyotrophic lateral sclerosis (ALS) by taming the systemic inflammation caused by gut bacteria leaking into the bloodstream, according to a new analysis of Phase 2 trial data. The findings point to microbial translocation, which occurs when bacteria break through…

The ALS Association and Paralyzed Veterans of America (PVA) are pressing the Congress to pass legislation boosting the financial support given the spouses and dependents of U.S. veterans whose death comes after nearly a decade of living with amyotrophic lateral sclerosis (ALS) due to their service. Specifically, the…

An international team of researchers discovered how, during development, motor neurons — the nerve cells controlling movement whose death causes amyotrophic lateral sclerosis (ALS) — direct blood vessel growth around them while growing toward target muscles. Specifically, motor neurons were found to secrete a combination of signaling molecules that…

When Juan heard, "you have ALS," his world went spinning. He learned how the right support could help him face his new challenges. Hear how his family and the ALS community rallied around Juan when he needed it most.

Early treatment with CNM-Au8 continues to demonstrate survival benefits in people with amyotrophic lateral sclerosis (ALS) compared with those who started treatment nine months later, according to an update from its developer, Clene Nanomedicine. The updated results come from the RESCUE-ALS Phase 2 trial (NCT04098406) and its open-label…

The U.S. Department of Defense (DOD) has awarded a $1.475 million grant to Aclipse Therapeutics to advance M102 — an experimental oral therapy for amyotrophic lateral sclerosis (ALS) — into first-in-human clinical trials. The therapeutic development award comes from the Congressionally Directed Medical Research Programs (CDMRP) at the…